Kinaxo Biotechnologies GmbH announced that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement Kinaxo will apply its phosphoproteomics technology PhosphoScout to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.

Kinaxo’s phosphoproteomics platform PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using state-of-the-art quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not requir antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signalling pathways. This positions PhosphoScout as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.

Kinaxo Biotechnologies is a privately-held biotechnology service company based in Munich/Martinsried, Germany. Kinaxo offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug re-positioning.